Mobile

A four-week trial evaluating the efficacy, safety and tolerance of GRT6005, a new centrally acting analgesic, in patients with pain due to diabetic nerve damages

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-022557-42

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the analgesic efficacy of fixed doses of 25 µg, 75 µg, and 200 µg GRT6005 once daily compared to placebo in subjects with moderate to severe pain due to diabetic polyneuropathy.

Critère d'inclusion

  • Pain due to diabetic polyneuropathy

Liens